Reducing potential overuse of dementia drugs could lead to considerable savings
- Collection:
- Health Policy and Services Research
- Series Title(s):
- Insight on the issues (AARP Public Policy Institute)
- Author(s):
- Carter, Elizabeth A., author Purvis, Leigh, author
- Contributor(s):
- AARP (Organization), issuing body. Public Policy Institute (AARP (Organization)), issuing body.
- Publication:
- Washington, DC : AARP Public Policy Institute, August 2018
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Dementia -- drug therapy Dementia -- economics Drug Costs Inappropriate Prescribing -- economics Aged Cholinesterase Inhibitors -- economics Cholinesterase Inhibitors -- therapeutic use Cost Savings Drug Therapy, Combination Memantine -- economics Memantine -- therapeutic use Humans United States
- Genre(s):
- Technical Report
- Abstract:
- Dementia medications typically provide modest, short-term benefits and have no proven effectiveness beyond one year of use. Nevertheless, our findings indicate that some adults with dementia remained on these drugs for as long as a decade, increasing the potential for adverse health outcomes and costing patients and insurers nearly $20,000. As much as 90 percent of this spending occurred after drug treatment was no longer supported by clinical evidence.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY-NC-ND license. (More information)
- Extent:
- 1 online resource (1 PDF file (6 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 101743455 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/101743455